

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/089370 A1

(51) International Patent Classification:

A61P 25/28 (2006.01) C07D 493/04 (2006.01)
C07D 471/04 (2006.01) C07D 493/10 (2006.01)
C07D 487/04 (2006.01) C07D 498/04 (2006.01)
C07D 487/10 (2006.01) C07D 513/04 (2006.01)

(21) International Application Number:

PCT/JP2024/038053

(22) International Filing Date:

25 October 2024 (25.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/JP2023/038720

26 October 2023 (26.10.2023) JP

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: SUZUKI, Masaki; c/o OTSUKA PHAR-
MACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku,
Osaka-shi, Osaka, 5400021 (JP). BERDINI, Valerio;
c/o Astex Therapeutics Ltd, 436 Cambridge Science
Park, Milton Road, Cambridge CB4 0QA (GB). YUKI,
Yohei; c/o OTSUKA PHARMACEUTICAL CO., LTD.,
3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP).
TAMANINI, Emiliano; c/o Astex Therapeutics Ltd, 436
Cambridge Science Park, Milton Road, Cambridge CB4
0QA (GB). IIDA, Masatoshi; c/o OTSUKA PHARMA-
CEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osa-
ka-shi, Osaka, 5400021 (JP). WALSH, Louise Marie; c/
o Astex Therapeutics Ltd, 436 Cambridge Science Park,
Milton Road, Cambridge CB4 0QA (GB). SOMEYA, Hi-
denori; c/o OTSUKA PHARMACEUTICAL CO., LTD.,
3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP).
OSBORNE, James Daniel; c/o Astex Therapeutics Ltd,
436 Cambridge Science Park, Milton Road, Cambridge
CB4 0QA (GB). FUJIWARA, Hideto; c/o OTSUKA
PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-
ku, Osaka-shi, Osaka, 5400021 (JP).

(74) Agent: YAMAO, Norihito et al.; AOYAMA & PART-
NERS, Osaka Umeda Twin Towers North, 8-1, Kaku-
da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS AS CSF1R INHIBITORS



(57) Abstract: Disclosed are pyrazolopyridine or pyrazolopyrimidine compounds, or salts thereof, with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with CSF1R, and methods of preparing said compounds, or salts thereof. Provided include a compound represented by Formula [I], or a salt thereof, wherein R¹ is hydrogen, etc.; R²¹ and R²² are hydrogen, or R²¹ and R²² together with the adjacent heterocyclic form a bridged bicyclic ring; R³ is -L³¹-R³¹ optionally substituted with one or more R³², or R³¹ optionally substituted with one or more R³²; L³¹ is -C(=O)-, etc.; R³¹ is C₁₋₆ alkyl, etc.; R³² is each independently halogen, etc.; and X is CR¹ or N; medical use thereof, and methods of preparation thereof.

WO 2025/089370 A1